Lymphoma, Intermediate-Grade
3 clinical trials · Condition
◉ Watch Lymphoma, Intermediate-Grade
| Record | Firm | Date |
|---|---|---|
| Ofatumumab In Older Patients With Untreated Low Or Intermediate Risk Indolent B-Cell Lymphomas (NCT01263418) | UNC Lineberger Comprehensive Cancer Center | 2011-06-01 |
| Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL (NCT00546793) | Gilead Sciences | 2008-01-01 |
| FCM Versus R-FCM Followed by R-Maintenance or Observation Only (NCT00317096) | Ludwig-Maximilians - University of Munich | 1998-11-01 |
Track Lymphoma, Intermediate-Grade automatically
Every clearance here is in the API, with alerts when new ones post.